Clinical Trial Detail

NCT ID NCT01773395
Title GVAX vs. Placebo for MDS/AML After Allo HSCT
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Busulfan + Fludarabine + Methotrexate + Tacrolimus

Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus

Age Groups: adult senior

No variant requirements are available.